中文 English

BRCAimTM Tumor Susceptibility Gene BRCA1/2 Screening Assay

Detection method

The multiplexed targeted sequencing method used with this assay, compared to PCR and first-generation sequencing methods, is able to simultaneously detect mutations in multiple genes or regions. More genetic information can be obtained from limited amounts patient samples and quickly.

Test significance

Provide medication guidance for PRAP inhibitor targeted drugs and platinum chemotherapy drugs treating ovarian cancer and breast cancer, as well as genetic risk and prognosis assessment for ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.

Product advantage

1) Covers the full coding region of BRCA1/2 genes.
2) Average on-target sequencing depth >300X.
3) Applicable for paraffin embedded tissue, saliva and blood samples.






Detection of genes

Tumor genes(2)

  • BRCA1
  • BRCA2

Covers all encoding sequence, including detection of SNVs and indels.

Applicable to cancer patients

The assay is applicable to cancer patients or populations without tumors, specifically:


Population

Applicable conditions

Major clinical value

Cancer patients

All ovarian cancer patients

Treatment guidance for PRAP inhibitors, genetic risk assessment.

Early-onset breast cancer (age of onset <45 years)

Treatment guidance of PRAP inhibitors and neoadjuvant chemotherapy, genetic risk and prognostic evaluation.

Triple negative breast cancer

Male breast cancer

Bilateral breast cancer or multiple primary tumors

Non-cancer patients

2 or more people in the family having breast cancer/ovarian cancer

Prevalence risk assessment.

Early-onset breast cancer patient with family history (age of onset <45 years)

Family members are susceptible to multiple cancer

Patients with breast hyperplasia/population attentive to their own health

Test procedure

*Product is for research use only.